News

Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...
Can Moderna Keep the Beat Streak Alive This Earnings Season?
Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...
MedPage Today on MSN8d
ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...
Morningstar24d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
“With an indication that also includes pregnant ... 2 Schmoele-Thoma B, Zareba AM, Jiang Q, et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Pharmabiz6d
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
“We are proud that Abrysvo has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect infants.” ...
PharmExec7d
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
MarketWatch24d
Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for ... for use in all adults. The New York drugmaker on Tuesday said the extended indication includes the prevention ...
Mirage News8d
ACIP Expands Pfizer RSV Vaccine for At-Risk Adults 50-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...